Global CAR-T Therapy Market Report 2022-2026 & 2031: Focus
Dublin, Aug. 03, 2022 (GLOBE NEWSWIRE) -- The "CAR-T Therapy Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The...
Stay updated with breaking news from Ar T. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dublin, Aug. 03, 2022 (GLOBE NEWSWIRE) -- The "CAR-T Therapy Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The...
In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call,...
Discover how combining CAR T cell therapy and antibody engineering can improve the effectiveness of cancer immunotherapy
Supply shortages and limited manufacturing capacity are leaving myeloma patients waiting months for CAR T-cell therapy, which offers a "last chance" after all other therapies have failed.
The new FDA approval for Breyanzi moves the Bristol Myers Squibb cancer cell therapy into an earlier line of treatment for an aggressive type of blood cancer. The decision also gives the pharmaceutical giant access to an additional pool of patients untapped by a rival cell therapy from Gilead Sciences.